{"result": "{\n    \"title\": \"Breast Cancer Community\",\n    \"summary\": \"The breast cancer community revolves around the treatment and diagnosis of breast cancer, with a focus on inflammatory breast cancer (IBC). The community is comprised of various entities, including medications, treatments, and medical professionals. The relationships between these entities are complex and multifaceted, with many entities being used in combination to treat breast cancer.\",\n    \"rating\": 8.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for serious health consequences and the complexity of the community's relationships.\",\n    \"findings\": [\n        {\n            \"summary\": \"IBC is a high-risk disease\",\n            \"explanation\": \"IBC is a type of breast cancer that is characterized by rapid onset and aggressive growth. It is a high-risk disease with a poor overall survival rate. [Data: Entities (48, 85, 87); Relationships (30, 62, 75); Claims (53, 61)]\"\n        },\n        {\n            \"summary\": \"Chemotherapy is a treatment option\",\n            \"explanation\": \"Chemotherapy is a potential treatment option for IBC, with various medications being used in combination to treat the disease. [Data: Entities (80, 85, 87); Relationships (40, 62, 75); Claims (55, 60)]\"\n        },\n        {\n            \"summary\": \"Targeted therapy is a treatment option\",\n            \"explanation\": \"Targeted therapy is a potential treatment option for IBC, with various medications being used to target specific proteins and pathways. [Data: Entities (85, 87, 348); Relationships (75, 85, 348); Claims (55, 96)]\"\n        },\n        {\n            \"summary\": \"Immune checkpoint inhibitors are a treatment option\",\n            \"explanation\": \"Immune checkpoint inhibitors are a potential treatment option for IBC, with various medications being used to enhance the immune response. [Data: Entities (348, 346); Relationships (85, 348, 346); Claims (55, 98)]\"\n        },\n        {\n            \"summary\": \"Multidisciplinary teams are involved in treatment\",\n            \"explanation\": \"Multidisciplinary teams of medical professionals, including oncologists, radiologists, and pathologists, are involved in the treatment of IBC. [Data: Entities (71, 72, 73); Relationships (40, 62, 75); Claims (55, 56)]\"\n        }\n    ]\n}", "input": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n48,\"\"\"IBC\"\"\",\"Here is a comprehensive summary of the data provided:\n\nIBC stands for Inflammatory Breast Cancer, a type of breast cancer characterized by rapid onset and aggressive growth. It is a high-risk disease and a type of breast cancer that carries a high risk for recurrence. IBC is a type of breast cancer that is invasive and has spread to the lymph nodes or other parts of the body, and is classified as a high-risk disease. It is characterized by inflammation and has been studied in the context of immunotherapy.\n\nIBC is a type of breast cancer that is associated with PD-L1 expression and has been studied in the context of brain metastasis and survival outcomes. It is treated with various systemic treatments, including trastuzumab and pertuzumab, and may be treated with trastuzumab and lapatinib. IBC is also included in the KRISTINE trial and the NeoSphere trial.\n\nIBC is a type of breast cancer that is locally advanced and metastatic, and has poor outcomes. It is a type of breast cancer that is characterized by the presence of cancer cells in the milk ducts or lobules, and is included in the working group focused on inflammatory breast cancer, of which Vicente Valero is a member.\n\nIn summary, IBC is a type of breast cancer that is characterized by inflammation, is high-risk and recurrent, and is treated with various systemic treatments. It is associated with PD-L1 expression and has been studied in the context of brain metastasis and survival outcomes.\",54\r\n85,\"\"\"PACLITAXEL\"\"\",\"Here is a comprehensive summary of the data provided:\n\n\"\"PACLITAXEL\"\" is a chemotherapy agent used to treat breast cancer, specifically in the treatment of HER2-negative locally advanced breast cancer (LABC) or inflammatory breast cancer (IBC). It is a chemotherapy drug studied in various clinical trials and has been evaluated for its effectiveness in treating breast cancer. PACLITAXEL is used in combination with other medications, such as pembrolizumab, bevacizumab, trastuzumab, and lapatinib, to treat breast cancer. It is also used as a single agent in the treatment regimen for breast cancer. PACLITAXEL is a type of chemotherapy medication used in the treatment of breast cancer, and it is a treatment option for IBC patients.\",8\r\n87,\"\"\"ANTHRACYCLINE\"\"\",\"Here is a comprehensive summary of the data:\n\nAnthracycline is a chemotherapy agent used to treat breast cancer. It is a type of chemotherapy specifically designed to combat breast cancer.\n\nNote: I resolved the contradictions by combining the two descriptions into a single, coherent summary.\",1\r\n252,\"\"\"ANTHRACYCLINE-BASED CHEMOTHERAPY\"\"\",\"\"\"Anthracycline-based Chemotherapy is a type of chemotherapy used in the treatment of IBC.\"\"\",1\r\n347,\"\"\"ANTI-EGFR AGENT\"\"\",\"\"\"Anti-EGFR agents are a type of targeted therapy that targets the EGFR protein, which is overexpressed in IBC.\"\"\",1\r\n348,\"\"\"ANTI\u2013PD-L1 ANTIBODY\"\"\",\"\"\"Anti-PD-L1 antibodies are a type of immune checkpoint inhibitor that helps the immune system fight cancer, including IBC.\"\"\",1\r\n353,\"\"\"BC\"\"\",No Description,1\r\n334,\"\"\"BERTUCCI ET AL.\"\"\",\"\"\"Bertucci et al. is a research group that reported PD-L1 overexpression in breast cancer tumors.\"\"\",1\r\n215,\"\"\"CARBOPLATIN\"\"\",\"Here is a comprehensive summary of the data:\n\nCarboplatin is a chemotherapy agent used in the treatment of various types of cancer, including breast cancer and inflammatory breast cancer (IBC). It is a chemotherapy drug that is often used in combination with other medications to treat cancer. Specifically, Carboplatin is used in the treatment of breast cancer, and it is also used to treat IBC. Additionally, it is classified as a type of cancer treatment and a type of chemotherapy used in the treatment of IBC. Overall, Carboplatin is a medication used in cancer treatment, specifically in the treatment of breast cancer and IBC.\",1\r\n80,\"\"\"CHEMOTHERAPY\"\"\",\"Here is a comprehensive summary of the data:\n\nChemotherapy is a type of systemic treatment that uses chemicals to kill cancer cells, including those associated with breast cancer, including inflammatory breast cancer (IBC). It is a treatment option for breast cancer, including IBC, and is evaluated in clinical trials for its effectiveness in treating the disease. Specifically, chemotherapy is combined with T-DM1 in the TCHP regimen, a treatment approach that has shown promise in the fight against breast cancer. Overall, chemotherapy is a widely used and effective treatment for breast cancer, including IBC, that has been shown to be effective in clinical trials and is often used in combination with other treatments.\",1\r\n74,\"\"\"DIAGNOSTIC RADIOLOGIST\"\"\",\"\"\"Diagnostic radiologist is a type of doctor who specializes in the interpretation of imaging tests.\"\"\",1\r\n89,\"\"\"DITSCH ET AL.\"\"\",\"\"\"Ditsch et al. are researchers who conducted a study on chemotherapy dose intensity in IBC patients.\"\"\",1\r\n88,\"\"\"FAC REGIMEN\"\"\",\"\"\"FAC regimen is a chemotherapy treatment protocol.\"\"\",1\r\n71,\"\"\"MEDICAL ONCOLOGIST\"\"\",\"\"\"Medical oncologist is a type of doctor who specializes in cancer treatment.\"\"\",1\r\n72,\"\"\"SURGEON\"\"\",\"\"\"Surgeon is a type of doctor who specializes in surgical procedures.\"\"\",1\r\n73,\"\"\"PATHOLOGIST\"\"\",\"\"\"Pathologist is a type of doctor who specializes in the diagnosis of diseases through the examination of tissues and cells.\"\"\",1\r\n84,\"\"\"MD ANDERSON\"\"\",No Description,1\r\n106,\"\"\"NON-IBC\"\"\",\"Here is a comprehensive summary of the data:\n\nNon-IBC (Non-Inflammatory Breast Cancer) refers to a type of breast cancer that is not Inflammatory Breast Cancer (IBC). Notably, Non-IBC has a similar pathological complete response (pCR) rate to ER-negative IBC, indicating that it shares some similarities with IBC in terms of treatment outcomes.\",1\r\n285,\"\"\"TALIMOGENE LAHERPAREPVEC\"\"\",\"Here is a comprehensive summary of the data:\n\nTalimogene laherparepvec is a treatment regimen. Specifically, it is a treatment regimen for local recurrence IBC (inflammatory breast cancer) or inoperable non-IBC (non-inflammatory breast cancer).\",1\r\n319,\"\"\"MULTIDISCIPLINARY TEAM\"\"\",\"Here is a comprehensive summary of the data:\n\nThe MULTIDISCIPLINARY TEAM is a group of healthcare professionals who work together to provide comprehensive care for patients with breast cancer. This team of experts evaluates and treats patients with breast cancer, offering a collaborative approach to patient care.\",1\r\n346,\"\"\"IMMUNE CHECKPOINT INHIBITOR\"\"\",\"\"\"Immune checkpoint inhibitors are a type of treatment that helps the immune system fight cancer, including IBC.\"\"\",1\r\n351,\"\"\"LAABC\"\"\",\"\"\"LAABC is a type of breast cancer that is different from IBC.\"\"\",1\r\n352,\"\"\"LA BC\"\"\",\"\"\"LA BC is an abbreviation for Localized Adenocarcinoma Breast Cancer, a type of breast cancer.\"\"\",1\r\n38,\"\"\"TUMOR EMBOLI\"\"\",\"Here is a comprehensive summary of the data:\n\nTumor emboli refer to the presence of tumor cells in the lymphatic vessels, which may be present or absent in biopsy specimens.\",1\r\n41,\"\"\"LYMPHEDEMA\"\"\",\"\"\"Lymphedema is a condition characterized by swelling caused by tumor emboli within dermal lymphatics.\"\"\",1\r\n90,\"\"\"ESTROGEN RECEPTOR\"\"\",No Description,1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n72,\"\"\"IBC\"\"\",\"\"\"TRASTUZUMAB\"\"\",\"\"\"Trastuzumab is used in the treatment of IBC, a type of breast cancer.\"\"\",69\r\n30,\"\"\"BREAST CANCER\"\"\",\"\"\"IBC\"\"\",\"\"\"IBC is a subtype of Breast Cancer that requires specific treatment.\"\"\",63\r\n52,\"\"\"IBC\"\"\",\"\"\"PCR\"\"\",\"Here is a comprehensive summary of the data:\n\nIBC (Inflammatory Breast Cancer) patients who achieve pCR (Pathological Complete Response) have better survival outcomes than those who do not. pCR is a measure of the effectiveness of treatment for IBC, indicating that the treatment has successfully eliminated all cancer cells from the breast tissue.\",62\r\n62,\"\"\"IBC\"\"\",\"\"\"PACLITAXEL\"\"\",\"Here is a comprehensive summary of the data:\n\nIBC (Inflammatory Breast Cancer) is a type of breast cancer that can be treated with Paclitaxel, a chemotherapy medication. According to the descriptions, Paclitaxel is used as part of a neoadjuvant regimen to treat IBC patients, and it is also used to treat IBC patients directly. Additionally, Paclitaxel is used to treat IBC, a type of breast cancer. Overall, Paclitaxel is a treatment option for IBC patients, and its use is likely part of a comprehensive treatment plan that may include other medications and therapies.\",62\r\n75,\"\"\"IBC\"\"\",\"\"\"NERATINIB\"\"\",\"\"\"Neratinib is used in adjuvant therapy for high-risk recurrent disease like IBC.\"\"\",62\r\n40,\"\"\"SYSTEMIC TREATMENT\"\"\",\"\"\"IBC\"\"\",\"\"\"IBC is treated with systemic treatment, including chemotherapy and targeted therapy.\"\"\",62\r\n53,\"\"\"IBC\"\"\",\"\"\"OS\"\"\",\"\"\"IBC patients have poor overall survival rates, with a 5-year OS rate of less than 5%.\"\"\",61\r\n89,\"\"\"IBC\"\"\",\"\"\"PD-L1\"\"\",\"\"\"IBC is associated with PD-L1, an immune checkpoint molecule found in tumor cells and TILs.\"\"\",61\r\n91,\"\"\"IBC\"\"\",\"\"\"INSTITUTE\"\"\",\"\"\"Institute demonstrates IBC preclinical data supporting a combination of targeted therapy and an immune checkpoint inhibitor.\"\"\",61\r\n85,\"\"\"IBC\"\"\",\"\"\"PEMBROLIZUMAB\"\"\",\"\"\"Pembrolizumab is used in the treatment of IBC, a type of breast cancer characterized by rapid onset and aggressive growth.\"\"\",60\r\n74,\"\"\"IBC\"\"\",\"\"\"OVERMOYER ET AL.\"\"\",\"\"\"Overmoyer et al. reported the efficacy of a neoadjuvant treatment for IBC patients, which is a high-risk disease.\"\"\",59\r\n67,\"\"\"IBC\"\"\",\"\"\"HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION\"\"\",\"\"\"High-dose chemotherapy with autologous hematopoietic stem cell transplantation is a treatment option for IBC.\"\"\",58\r\n73,\"\"\"IBC\"\"\",\"\"\"NEOSPHERE TRIAL\"\"\",\"\"\"The NeoSphere trial included 29 IBC patients.\"\"\",58\r\n76,\"\"\"IBC\"\"\",\"\"\"PANITUMUMAB\"\"\",\"\"\"Panitumumab is used in certain circumstances for IBC cases, targeting EGFR expression.\"\"\",58\r\n77,\"\"\"IBC\"\"\",\"\"\"EGFR\"\"\",\"\"\"EGFR expression is associated with worse prognosis in IBC cases.\"\"\",58\r\n78,\"\"\"IBC\"\"\",\"\"\"HER2+ IBC\"\"\",\"\"\"HER2+ IBC is a subtype of IBC.\"\"\",58\r\n71,\"\"\"IBC\"\"\",\"\"\"LABC\"\"\",\"\"\"LABC includes IBC, a type of breast cancer with high-risk characteristics.\"\"\",57\r\n87,\"\"\"IBC\"\"\",\"\"\"BERCKELAER ET AL.\"\"\",\"\"\"Berckelaer et al. studied PD-L1 expression in TILs in the context of IBC.\"\"\",57\r\n88,\"\"\"IBC\"\"\",\"\"\"ARIAS-PULIDO ET AL.\"\"\",\"\"\"Arias-Pulido et al. studied PD-L1 positivity in IBC samples.\"\"\",57\r\n90,\"\"\"IBC\"\"\",\"\"\"TILS\"\"\",\"Here is a comprehensive summary of the data:\n\nThe entities \"\"IBC\"\" and \"\"TILs\"\" are related to each other. TILs (Tumor-Infiltrating Lymphocytes) are found in the tumor microenvironment of IBC (Invasive Breast Cancer). Additionally, TILs are more frequently found in IBC compared to non-IBC.\",57\r\n3,\"\"\"VICENTE VALERO\"\"\",\"\"\"IBC\"\"\",\"\"\"Vicente Valero is a member of the IBC working group.\"\"\",57\r\n43,\"\"\"IMMUNOTHERAPY\"\"\",\"\"\"IBC\"\"\",\"Here is a comprehensive summary of the data:\n\nIMMUNOTHERAPY is a potential treatment option for Inflammatory Breast Cancer (IBC).\",57\r\n58,\"\"\"IBC\"\"\",\"\"\"RADIATION ONCOLOGIST\"\"\",\"\"\"Radiation oncologists are part of a multidisciplinary team that treats IBC patients.\"\"\",56\r\n61,\"\"\"IBC\"\"\",\"\"\"CRISTOFANILLI ET AL.\"\"\",\"\"\"Cristofanilli et al. conducted a study on IBC patients.\"\"\",56\r\n63,\"\"\"IBC\"\"\",\"\"\"FAC\"\"\",\"\"\"FAC is used to treat IBC patients.\"\"\",56\r\n68,\"\"\"IBC\"\"\",\"\"\"INTERNATIONAL EXPERT CONSENSUS\"\"\",\"\"\"International Expert Consensus provides guidance on the treatment of IBC.\"\"\",56\r\n70,\"\"\"IBC\"\"\",\"\"\"STANDARD OF CARE\"\"\",\"\"\"IBC is treated according to the Standard of Care, which involves the use of various therapies, including chemotherapy and transplantation.\"\"\",56\r\n79,\"\"\"IBC\"\"\",\"\"\"TARGETED THERAPY\"\"\",\"\"\"Targeted Therapy is a treatment option for IBC.\"\"\",56\r\n81,\"\"\"IBC\"\"\",\"\"\"TAXANE-BASED CHEMOTHERAPY\"\"\",\"\"\"Taxane-based Chemotherapy is used in the treatment of IBC.\"\"\",56\r\n92,\"\"\"IBC\"\"\",\"\"\"KEYNOTE-522\"\"\",\"\"\"IBC is the disease being treated in the KEYNOTE-522 clinical trial.\"\"\",56\r\n93,\"\"\"IBC\"\"\",\"\"\"I-SPY2\"\"\",\"\"\"IBC is the disease being treated in the I-SPY2 clinical trial.\"\"\",56\r\n64,\"\"\"IBC\"\"\",\"\"\"ANTHRACYCLINE\"\"\",\"\"\"Anthracycline is used to treat IBC patients.\"\"\",55\r\n80,\"\"\"IBC\"\"\",\"\"\"ANTHRACYCLINE-BASED CHEMOTHERAPY\"\"\",\"\"\"Anthracycline-based Chemotherapy is used in the treatment of IBC.\"\"\",55\r\n95,\"\"\"IBC\"\"\",\"\"\"ANTI-EGFR AGENT\"\"\",\"\"\"Anti-EGFR agents are a potential treatment for IBC.\"\"\",55\r\n96,\"\"\"IBC\"\"\",\"\"\"ANTI\u2013PD-L1 ANTIBODY\"\"\",\"\"\"Anti-PD-L1 antibodies are a potential treatment for IBC.\"\"\",55\r\n98,\"\"\"IBC\"\"\",\"\"\"BC\"\"\",\"\"\"BC is related to IBC as a medical organization or institution may be involved in the study and treatment of IBC.\"\"\",55\r\n86,\"\"\"IBC\"\"\",\"\"\"BERTUCCI ET AL.\"\"\",\"\"\"Bertucci et al. reported PD-L1 overexpression in IBC tumors.\"\"\",55\r\n82,\"\"\"IBC\"\"\",\"\"\"CARBOPLATIN\"\"\",\"\"\"Carboplatin is used in the treatment of IBC.\"\"\",55\r\n60,\"\"\"IBC\"\"\",\"\"\"CHEMOTHERAPY\"\"\",\"Here is a comprehensive summary of the data:\n\nIBC (Inflammatory Breast Cancer) is a type of breast cancer that can be treated with chemotherapy. According to the descriptions, chemotherapy is a potential treatment option for IBC, and it has been reported to be effective in treating the disease. Specifically, chemotherapy has been used to treat IBC with a reported objective response rate of 74% and a median overall survival (OS) of 37 months.\",55\r\n57,\"\"\"IBC\"\"\",\"\"\"DIAGNOSTIC RADIOLOGIST\"\"\",\"\"\"Diagnostic radiologists are part of a multidisciplinary team that treats IBC patients.\"\"\",55\r\n66,\"\"\"IBC\"\"\",\"\"\"DITSCH ET AL.\"\"\",\"\"\"Ditsch et al. conducted a study on chemotherapy dose intensity in IBC patients.\"\"\",55\r\n65,\"\"\"IBC\"\"\",\"\"\"FAC REGIMEN\"\"\",\"\"\"FAC regimen is used to treat IBC, a type of breast cancer.\"\"\",55\r\n54,\"\"\"IBC\"\"\",\"\"\"MEDICAL ONCOLOGIST\"\"\",\"\"\"Medical oncologists are part of a multidisciplinary team that treats IBC patients.\"\"\",55\r\n55,\"\"\"IBC\"\"\",\"\"\"SURGEON\"\"\",\"\"\"Surgeons are part of a multidisciplinary team that treats IBC patients.\"\"\",55\r\n56,\"\"\"IBC\"\"\",\"\"\"PATHOLOGIST\"\"\",\"\"\"Pathologists are part of a multidisciplinary team that treats IBC patients.\"\"\",55\r\n59,\"\"\"IBC\"\"\",\"\"\"MD ANDERSON\"\"\",\"\"\"MD Anderson conducted a retrospective study on IBC patients, providing insights into the treatment of IBC.\"\"\",55\r\n69,\"\"\"IBC\"\"\",\"\"\"NON-IBC\"\"\",\"\"\"IBC and non-IBC are compared in terms of OS rate and outcomes.\"\"\",55\r\n83,\"\"\"IBC\"\"\",\"\"\"TALIMOGENE LAHERPAREPVEC\"\"\",\"\"\"Talimogene laherparepvec is a treatment for IBC patients, specifically for TNBC patients.\"\"\",55\r\n84,\"\"\"IBC\"\"\",\"\"\"MULTIDISCIPLINARY TEAM\"\"\",\"\"\"The Multidisciplinary team evaluates and treats patients with IBC, a type of breast cancer that is invasive and has spread to the lymph nodes or other parts of the body.\"\"\",55\r\n94,\"\"\"IBC\"\"\",\"\"\"IMMUNE CHECKPOINT INHIBITOR\"\"\",\"\"\"Immune checkpoint inhibitors are a potential treatment for IBC.\"\"\",55\r\n97,\"\"\"IBC\"\"\",\"\"\"LAABC\"\"\",\"\"\"LAABC is different from IBC.\"\"\",55\r\n99,\"\"\"IBC\"\"\",\"\"\"LA BC\"\"\",\"\"\"IBC is distinct from LA BC as a unique entity with different characteristics and treatment approaches.\"\"\",55\r\n46,\"\"\"TUMOR EMBOLI\"\"\",\"\"\"IBC\"\"\",\"\"\"IBC is characterized by the presence of tumor emboli in dermal lymphatics, which may be present or absent in biopsy specimens.\"\"\",55\r\n47,\"\"\"LYMPHEDEMA\"\"\",\"\"\"IBC\"\"\",\"\"\"IBC is characterized by lymphedema caused by tumor emboli within dermal lymphatics.\"\"\",55\r\n143,\"\"\"PACLITAXEL\"\"\",\"\"\"TRASTUZUMAB\"\"\",\"\"\"Trastuzumab is combined with paclitaxel in a treatment for breast cancer.\"\"\",23\r\n142,\"\"\"PACLITAXEL\"\"\",\"\"\"LAPATINIB\"\"\",\"Here is a comprehensive summary of the data:\n\nPACLITAXEL and LAPATINIB are two medications used in cancer treatment. Specifically, they are combined in a treatment for breast cancer, where LAPATINIB is paired with PACLITAXEL to provide a comprehensive treatment approach. Additionally, both medications have different effects on the pCR (pathological complete response) rate, indicating that they have distinct mechanisms of action in cancer treatment.\",20\r\n140,\"\"\"PACLITAXEL\"\"\",\"\"\"NAC\"\"\",\"\"\"Paclitaxel is part of the NAC regimen.\"\"\",19\r\n144,\"\"\"PACLITAXEL\"\"\",\"\"\"BEVACIZUMAB\"\"\",\"\"\"Paclitaxel is used in certain circumstances with bevacizumab for metastatic breast cancer.\"\"\",16\r\n141,\"\"\"PACLITAXEL\"\"\",\"\"\"OVERMOYER ET AL.\"\"\",\"\"\"Overmoyer et al. reported the efficacy of neoadjuvant weekly paclitaxel combined with pertuzumab and trastuzumab.\"\"\",13\r\n145,\"\"\"PACLITAXEL\"\"\",\"\"\"AC REGIME\"\"\",\"\"\"AC regime and paclitaxel are used together in a chemotherapy regimen for breast cancer treatment.\"\"\",10\r\n139,\"\"\"PACLITAXEL\"\"\",\"\"\"ESTROGEN RECEPTOR\"\"\",\"\"\"Estrogen receptor is relevant to paclitaxel's effectiveness in treating breast cancer.\"\"\",9\r\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "parameters": {"model": "llama3-8b-8192", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 2000, "n": null}}